Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib therapy in pulmonary tumor thrombotic microangiopathy (PTTM)
jRCTs031210263Active, not recruiting
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of imatinib in Pulmonary tumor thrombotic microangiopathy (PTTM), pulmonary hypertension (PH) and cancer. Primary endpoint: Overall survival. Started Oct 2021; status: active, not recruiting.
02
Drugs
03
Conditions
Pulmonary tumor thrombotic microangiopathy (PTTM)pulmonary hypertension (PH)cancer
Beyond the preview
Go deeper on jRCTs031210263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031210263.